Aspirin, losartan and simvastatin in hospitalised COVID-19 patients: a multinational randomised open-label factorial trial

ondon School of Hygiene and Tropical Medicine0 个研究点目标入组 10,000 人开始时间: 2020年5月12日最近更新: 2023年5月29日

适应症

试验速览

暂无简介。

•Adults age 40 years and older
•with suspected or confirmed acute COVID-19 infection (We use the following WHO criteria for a suspected case: A. A patient with acute respiratory illness (fever and at least one sign or symptom of respiratory disease, e.g., cough, shortness of breath), AND a history of travel to or residence in a location reporting community transmission of COVID-19 disease during the 14 days prior to symptom onset; OR B. A patient with any acute respiratory illness AND having been in contact with a confirmed or probable COVID-19 case in the last 14 days prior to symptom onset; OR C. A patient with severe acute respiratory illness (fever and at least one sign/symptom of respiratory disease, e.g., cough, shortness of breath; AND requiring hospitalization) AND in the absence of an alternative diagnosis that fully explains the clinical presentation.)
•requiring hospitalisation

•Women known to be pregnant
•Patients hospitalised without symptoms of acute COVID-19 infection should not be recruited even if they test positive for COVID-19
•Patients already receiving mechanical ventilation via an endotracheal tube
•Patients already receiving any of the trial treatments
•Patients with a definite indication or contraindication for any of the trial treatments.
•Patients who are very severely frail (completely dependent and approaching end of life who typically they could not recover even from a mild illness) or terminally ill should not be recruited.

发起方

ondon School of Hygiene and Tropical Medicine